ALP Bio

ALP Bio is a Swiss biotech startup that develops an immune organoid and AI platform to predict and mitigate immunogenicity risks in therapeutic antibodies. Targeting pharmaceutical companies, they provide a hybrid platform combining human tonsil-derived ex vivo data with generative AI to enable earlier de-risking of drug pipelines. The company generates revenue by providing its platform to drug developers and planning to co-develop biobetter assets.